I-Mab Appoints Wei Fu as Executive Chairman
Ticker: NBP · Form: 6-K · Filed: Sep 8, 2025 · CIK: 1778016
Sentiment: neutral
Topics: executive-appointment, management-change
TL;DR
I-Mab just named Wei Fu as Executive Chairman, effective Sept 3rd.
AI Summary
On September 3, 2025, I-Mab's Board of Directors appointed Mr. Wei Fu as the Executive Chairman. The filing also notes the appointment of other officers, though specific names and details are not provided in this excerpt. I-Mab is a pharmaceutical preparations company based in Rockville, MD.
Why It Matters
Changes in executive leadership can signal shifts in company strategy or operational focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is a routine update on executive appointments and does not contain significant financial or operational risks.
Key Players & Entities
- I-Mab (company) — Registrant
- Wei Fu (person) — Appointed Executive Chairman
- September 3, 2025 (date) — Effective date of appointment
- 20850 (location) — ZIP code for business and mail address
- Rockville, MD (location) — City and State for business and mail address
FAQ
Who was appointed as the Executive Chairman of I-Mab?
Mr. Wei Fu was appointed as the Executive Chairman of I-Mab.
When was the appointment of the Executive Chairman effective?
The appointment of Mr. Wei Fu as Executive Chairman was effective on September 3, 2025.
What is I-Mab's primary business sector?
I-Mab is in the Pharmaceutical Preparations sector, SIC code 2834.
What is the address of I-Mab's principal executive offices?
I-Mab's principal executive offices are located at Suite 400, 2440 Research Blvd, Rockville, MD 20850.
Does I-Mab file annual reports under Form 20-F or 40-F?
I-Mab files annual reports under Form 20-F.
Filing Stats: 1,034 words · 4 min read · ~3 pages · Grade level 9.7 · Accepted 2025-09-08 08:10:53
Key Financial Figures
- $1.39 — of the options granted to Mr. Wei Fu is $1.39 per Ordinary Share (equivalent to $3.19
- $3.19 — $1.39 per Ordinary Share (equivalent to $3.19 per ADS), the volume weighted average p
- $2.02 — the options granted to Dr. Sean Cao is $2.02 per Ordinary Share (equivalent to $4.65
- $4.65 — $2.02 per Ordinary Share (equivalent to $4.65 per ADS), the closing price of the Comp
- $8 — the Company’s ADS is at or above $8.00, $12.00, and $16.00, respectively. T
- $12 — pany’s ADS is at or above $8.00, $12.00, and $16.00, respectively. The optio
- $16 — s ADS is at or above $8.00, $12.00, and $16.00, respectively. The options granted t
- $8.00 — the Company’s ADS is at or above $8.00. The Board also approved the grant of r
Filing Documents
- giva_and_exec_updates_-_.htm (6-K) — 45KB
- imab-ex99_1.htm (EX-99.1) — 45KB
- imab-ex99_2.htm (EX-99.2) — 427KB
- imab-ex99_3.htm (EX-99.3) — 323KB
- imab-ex99_4.htm (EX-99.4) — 57KB
- img44095488_0.jpg (GRAPHIC) — 40KB
- imab-ex99_4s1.jpg (GRAPHIC) — 187KB
- imab-ex99_4s2.jpg (GRAPHIC) — 971KB
- imab-ex99_4s3.jpg (GRAPHIC) — 406KB
- imab-ex99_4s4.jpg (GRAPHIC) — 574KB
- imab-ex99_4s5.jpg (GRAPHIC) — 444KB
- imab-ex99_4s6.jpg (GRAPHIC) — 441KB
- imab-ex99_4s7.jpg (GRAPHIC) — 534KB
- imab-ex99_4s8.jpg (GRAPHIC) — 317KB
- imab-ex99_4s9.jpg (GRAPHIC) — 384KB
- imab-ex99_4s10.jpg (GRAPHIC) — 395KB
- imab-ex99_4s11.jpg (GRAPHIC) — 368KB
- imab-ex99_4s12.jpg (GRAPHIC) — 506KB
- imab-ex99_4s13.jpg (GRAPHIC) — 411KB
- imab-ex99_4s14.jpg (GRAPHIC) — 417KB
- imab-ex99_4s15.jpg (GRAPHIC) — 355KB
- imab-ex99_4s16.jpg (GRAPHIC) — 311KB
- imab-ex99_4s17.jpg (GRAPHIC) — 397KB
- imab-ex99_4s18.jpg (GRAPHIC) — 509KB
- imab-ex99_4s19.jpg (GRAPHIC) — 431KB
- imab-ex99_4s20.jpg (GRAPHIC) — 390KB
- imab-ex99_4s21.jpg (GRAPHIC) — 310KB
- imab-ex99_4s22.jpg (GRAPHIC) — 319KB
- imab-ex99_4s23.jpg (GRAPHIC) — 263KB
- imab-ex99_4s24.jpg (GRAPHIC) — 290KB
- imab-ex99_4s25.jpg (GRAPHIC) — 292KB
- imab-ex99_4s26.jpg (GRAPHIC) — 414KB
- imab-ex99_4s27.jpg (GRAPHIC) — 378KB
- imab-ex99_4s28.jpg (GRAPHIC) — 351KB
- imab-ex99_4s29.jpg (GRAPHIC) — 260KB
- imab-ex99_4s30.jpg (GRAPHIC) — 426KB
- imab-ex99_4s31.jpg (GRAPHIC) — 297KB
- imab-ex99_4s32.jpg (GRAPHIC) — 377KB
- imab-ex99_4s33.jpg (GRAPHIC) — 534KB
- imab-ex99_4s34.jpg (GRAPHIC) — 164KB
- imab-ex99_4s35.jpg (GRAPHIC) — 440KB
- imab-ex99_4s36.jpg (GRAPHIC) — 449KB
- imab-ex99_4s37.jpg (GRAPHIC) — 399KB
- imab-ex99_4s38.jpg (GRAPHIC) — 375KB
- imab-ex99_4s39.jpg (GRAPHIC) — 194KB
- 0000950170-25-113369.txt ( ) — 21993KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. I-MAB By : /s/ Joseph Skelton Name : Joseph Skelton Title : Chief Financial Officer Date: September 8, 2025